Meeting
2017 ASCO Annual Meeting
Recurrence risk factors and outcome stratification in stage II colon cancer patients: A subanalysis of the SACURA trial.
Authors
Megumi Ishiguro
Tokyo Medical and Dental University, Department of Translational Oncology, Tokyo, Japan
Megumi Ishiguro , Eiji Nakatani , Hideki Ueno , Toshiaki Ishikawa , Hiroyuki Uetake , Yasuhiro Shimada , Keiichi Takahashi , Kenjiro Kotake , Masahiko Watanabe , Naohiro Tomita , Hidetaka Mochizuki , Satoshi Teramukai , Kenichi Sugihara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT00392899
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3611)
DOI
10.1200/JCO.2017.35.15_suppl.3611
Abstract #
3611
Poster Bd #
234
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).
First Author: Ken Kondo
Poster
2016 ASCO Annual Meeting
A randomized phase III trial of 1-year adjuvant chemotherapy with oral tegafur-uracil (UFT) vs. surgery alone in stage II colon cancer: SACURA trial.
First Author: Yoshiki Kajiwara
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic value of tumor budding in patients with stage II and III colon cancer: A single-institution experience.
First Author: David Viñal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Artificial intelligence (AI) -powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of prognosis in stage II-III resectable colon cancer.
First Author: Yoojoo Lim